The long-term safety and tolerability of insulin degludec (IDeg) was compared with that of insulin detemir (IDet), as basal treatment in participants with type 1 diabetes mellitus (T1DM). In the present multinational, 26-week core + 26-week extension, controlled, open-label, parallel-group trial, adults with T1DM were randomized to IDeg or IDet as basal insulin treatment combined with meal-time bolus insulin aspart. IDeg was administered once daily, whilst IDet was administered once or twice daily depending on patients' glycaemic control. After 1 year, IDeg provided a 33

作者：M, Davies；T, Sasaki；J L, Gross；G, Bantwal；Y, Ono；T, Nishida；D, Tojjar；H, Seino

来源：Diabetes, obesity & metabolism 2016 年 18卷 1期